Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial
Primary result · Composite of death from cardiovascular causes, non-fatal stroke, non-fatal myocardial infarction, ischaemia-related coronary revascularisation, or heart failure eventResult — go to the resultHazard ratio 0.89 95% CI 0.67–1.18Authors' conclusion
In participants with obesity with established cardiovascular disease or chronic kidney disease or at increased risk of cardiovascular disease, survodutide was not associated with increased risk for the primary composite endpoint of death from cardiovascular causes, non-fatal stroke, non-fatal myocardial infarction, ischaemia-related coronary revascularisation, or heart failure event compared with placebo. This cardiovascular safety trial provides clinicians with reassuring data that treatment with survodutide, a novel glucagon receptor-GLP-1 receptor dual agonist, is not associated with increased cardiovascular risk.
Study context
- Population
- Adults aged 18 years or older with a BMI of 27 kg/m² or greater and established cardiovascular disease or at least two obesity complications or risk factors for cardiovascular disease; participants with chronic kidney disease eligible if BMI of 30 kg/m² or greaterrandomly assigned, 5507 treated (23 not treated)
- Participants
- 5,530 adults
- Comparison
- Pooled survodutide compared with placebo
- Survodutide 3.6 mgn = 1,836
- Survodutide 6.0 mgn = 1,835
- Survodutide (pooled)n = 3,671
- Placebon = 1,836reference
- Primary endpoint
- Composite of:
- Death from cardiovascular causes
- Non-fatal stroke
- Non-fatal myocardial infarction
- Ischaemia-related coronary revascularisation
- Heart failure event
Methodological details524 clinical sites in 34 countries, non-inferiority margin 1.65 for the upper limit of the two-sided 95% CI of the HR, treatment-regimen estimand
- 524 clinical sites in 34 countries
- Non-inferiority margin 1.65 for the upper limit of the two-sided 95% CI of the HR
- Treatment-regimen estimand
Primary result
As reported in the abstract
Further findings
| Outcome | Survodutide 3.6 mg | Survodutide 6.0 mg | Placebo |
|---|---|---|---|
| Remained on treatment until study closeout | 56.0% | 56.6% | 59.0% |
Time in study
- Median time in study
- 22.0 months (IQR 20.1-23.7)
Safety
| Outcome | Survodutide 3.6 mg | Survodutide 6.0 mg | Placebo |
|---|---|---|---|
| Adverse events | 93.0% | 93.1% | 85.6% |
| Nausea | 48.0% | 49.0% | 12.1% |
| Vomiting | 31.7% | 34.0% | 4.8% |
| Gastrointestinal adverse events leading to treatment discontinuation | 19.3% | 20.8% | 1.9% |
| Serious adverse eventsSimilar rates across treatment groups | 22.5% | 20.8% | 23.9% |
| Fatal adverse eventsSimilar across treatment groups | 0.9% | 0.9% | 0.6% |
| Fatal adverse events due to cardiac disorders | 0.3% | 0.4% | 0.3% |
- Nausea: Gastrointestinal adverse events were more frequent with survodutide than in the placebo group
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →